<DOC>
	<DOCNO>NCT02035384</DOCNO>
	<brief_summary>This study conduct Europe , North South America . The aim study provide additional documentation immunogenicity , obtain additional clinical data , turoctocog alfa set normal clinical practise patient previously treat factor VIII agent ( FVIII ) .</brief_summary>
	<brief_title>Safety Efficacy Turoctocog Alfa During Long-Term Treatment Severe Moderately Severe Haemophilia A</brief_title>
	<detailed_description />
	<mesh_term>Hemophilia A</mesh_term>
	<mesh_term>Blood Coagulation Disorders</mesh_term>
	<mesh_term>Hemostatic Disorders</mesh_term>
	<mesh_term>Factor VIII</mesh_term>
	<criteria>Informed consent obtain studyrelated activity . Studyrelated activity procedure relate recording data accord protocol Previously FVIII treat ( 150 exposure day time first dose turoctocog alfa ) male patient diagnosis severe moderately severe haemophilia A ( FVIII equal 2 % ) The decision initiate treatment commercially available turoctocog alfa make patient/parent patient 's treat physician independently decision include patient study A negative FVIII inhibitor test obtain four week prior first dose turoctocog alfa Contraindications use accord approve product information text ( US Package insert ( PI ) , European Summary Product Characteristics ( SmPC ) , correspond local prescribe information ) Treatment investigational drug within 30 day prior enrolment study Previous participation clinical trial turoctocog alfa Treatment FVIII product initiation treatment turoctocog alfa</criteria>
	<gender>Male</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
</DOC>